文献速递脊柱外科骨质疏松与代谢性骨病

围手术期特立帕肽预防成人胸腰椎脊柱畸形术后骨质疏松患者近端交界性后凸与失败:一项前瞻性随机对照试验

Perioperative teriparatide for preventing proximal junctional kyphosis and failure in patients with osteoporosis after adult thoracolumbar spinal deformity surgery: a prospective randomized controlled trial.
PubMed 文献 · Osteoporos Int · 2025-03-18

这项随机对照试验纳入64例拟行成人脊柱畸形手术的骨质疏松患者,比较围手术期特立帕肽与地舒单抗(活性对照)对近端交界性后凸(PJK)和近端交界性失败(PJF)的预防效果。特立帕肽组PJF发生率显著低于地舒单抗组(3.4% vs 22.2%,p=0.034),PJK发生率数值较低但无统计学显著差异(17.2% vs 33.3%,p=0.165),且术后背痛VAS和EQ-5D显著改善。

要点

  • 特立帕肽组PJF发生率3.4%,显著低于地舒单抗组的22.2%(p=0.034)。
  • PJK发生率特立帕肽组17.2% vs 地舒单抗组33.3%,差异无统计学显著(p=0.165)。
  • 特立帕肽组术后背痛VAS和EQ-5D评分较地舒单抗组显著改善。

核心结论

  • 围手术期特立帕肽治疗成人脊柱畸形术后骨质疏松患者可有效降低PJF发生率和术后背痛。

研究设计与样本

  • 前瞻性随机对照试验,共纳入64例拟行成人脊柱畸形手术的骨质疏松患者,随机分为特立帕肽组和地舒单抗组。
  • 两组均从术前3个月至术后3个月按各自药物标准方案给药。
  • 主要结局为术后1年内PJK和PJF发生率,次要结局为患者报告结局、骨密度和髋部双能X线吸收法t值。

主要发现

  • 改良意向性治疗分析中,特立帕肽组PJK发生率17.2% vs 地舒单抗组33.3%,差异无统计学显著(p=0.165)。
  • 改良意向性治疗分析中,特立帕肽组PJF发生率3.4% vs 地舒单抗组22.2%,差异有统计学显著(p=0.034)。
  • 1年随访时两组髋部骨密度无显著差异。
  • 特立帕肽组术后背痛VAS和EQ-5D评分较地舒单抗组显著改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We conducted a randomized controlled trial to assess the preventive effect of perioperative teriparatide on proximal junctional kyphosis and proximal junctional failure (PJF) in osteoporosis patients undergoing adult spinal deformity surgery. Teriparatide (experimental group) and denosumab (active control) were administered. The teriparatide group demonstrated significantly better PJF incidence and VAS for back pain, EQ-5D than the control group. PURPOSE: This randomized controlled trial is aimed at investigating and comparing the effects of perioperative teriparatide and denosumab as an active control for preventing proximal junctional kyphosis (PJK) and proximal junctional failure (PJF) in patients with osteoporosis after adult spinal deformity (ASD) surgery. METHODS: A total of 64 patients with osteoporosis, who planned to undergo ASD surgery, were randomly assigned to the teriparatide and denosumab groups. Treatment with teriparatide or denosumab in both groups was conducted from 3 months preoperatively to 3 months postoperatively based on the standard regimen for each medication. The primary outcome was PJK and PJF incidence within 1 year after ASD surgery. The secondary outcomes were patient-reported outcomes (PROs), bone mineral density (BMD), and dual-energy X-ray absorptiometry (DEXA) t-score of the hip. RESULTS: The teriparatide group showed a lower incidence of PJK than the denosumab group (17.2% vs. 33.3%), although this difference was not statistically significant (p = 0.165 in a modified intention-to-treat (mITT) analysis). Furthermore, the teriparatide group exhibited a significantly lower incidence of PJF than the denosumab group (3.4% vs. 22.2%; p = 0.034 in the mITT analysis). As for the secondary outcomes, no significant differences in BMD of the hip were observed between the two groups at the 1-year follow-up. The teriparatide group showed significantly improved postoperative VAS for back pain and EQ-5D score. CONCLUSIONS: Perioperative teriparatide treatment of patients with osteoporosis after ASD surgery effectively reduced PJF incidence and postoperative back pain.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Park JH, Kwon O, Choi JH, et al. Perioperative teriparatide for preventing proximal junctional kyphosis and failure in patients with osteoporosis after adult thoracolumbar spinal deformity surgery: a prospective randomized controlled trial. Osteoporos Int. 2025. PMID: 40100350. doi:10.1007/s00198-025-07449-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。